Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Motoshi Ichikawa

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
International Journal of Hematology|January 5, 2021
Development of Philadelphia chromosome-negative acute myeloid leukemia with IDH2 and NPM1 mutations in a patient with chronic myeloid leukemia who showed a major molecular response to tyrosine kinase inhibitor therapyFumi Nakamura, Honoka Arai, Yasuhito Nannya, et al.
Lung Cancer (Amsterdam, Netherlands)|January 8, 2010
Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: a multi-center phase II studyMotoshi Ichikawa, Ryujiro Suzuki, Kensuke Kataoka, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 9, 2005
Crk-associated substrate lymphocyte type is required for lymphocyte trafficking and marginal zone B cell maintenanceSachiko Seo, Takashi Asai, Toshiki Saito, et al.
Genes to Cells : Devoted to Molecular & Cellular Mechanisms|June 11, 2004
Impaired spermatogenesis and male fertility defects in CIZ/Nmp4-disrupted miceTetsuya Nakamoto, Akiko Shiratsuchi, Hideaki Oda, et al.
International Journal of Hematology|July 13, 2022
ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trialYasuyoshi Morita, Yasuhito Nannya, Motoshi Ichikawa, et al.
Nature Communications|August 28, 2014
Recurrent CDC25C mutations drive malignant transformation in FPD/AMLAkihide Yoshimi, Takashi Toya, Masahito Kawazu, et al.
The Lancet. Infectious Diseases|July 7, 2015
Risk factors for 30-day mortality in patients with pneumonia who receive appropriate initial antibiotics: an observational cohort studyYuichiro Shindo, Ryota Ito, Daisuke Kobayashi, et al.
American Journal of Respiratory and Critical Care Medicine|July 17, 2013
Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumoniaYuichiro Shindo, Ryota Ito, Daisuke Kobayashi, et al.
International Journal of Hematology|May 4, 2022
Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trialYasushi Miyazaki, Toru Kiguchi, Shinya Sato, et al.
Leukemia|January 7, 2026
NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partnersKazuhisa Chonabayashi, Makoto Iwasaki, Junya Kanda, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
International Journal of Hematology|January 5, 2021
Development of Philadelphia chromosome-negative acute myeloid leukemia with IDH2 and NPM1 mutations in a patient with chronic myeloid leukemia who showed a major molecular response to tyrosine kinase inhibitor therapyFumi Nakamura, Honoka Arai, Yasuhito Nannya, et al.
Lung Cancer (Amsterdam, Netherlands)|January 8, 2010
Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: a multi-center phase II studyMotoshi Ichikawa, Ryujiro Suzuki, Kensuke Kataoka, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 9, 2005
Crk-associated substrate lymphocyte type is required for lymphocyte trafficking and marginal zone B cell maintenanceSachiko Seo, Takashi Asai, Toshiki Saito, et al.
Genes to Cells : Devoted to Molecular & Cellular Mechanisms|June 11, 2004
Impaired spermatogenesis and male fertility defects in CIZ/Nmp4-disrupted miceTetsuya Nakamoto, Akiko Shiratsuchi, Hideaki Oda, et al.
International Journal of Hematology|July 13, 2022
ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trialYasuyoshi Morita, Yasuhito Nannya, Motoshi Ichikawa, et al.
Nature Communications|August 28, 2014
Recurrent CDC25C mutations drive malignant transformation in FPD/AMLAkihide Yoshimi, Takashi Toya, Masahito Kawazu, et al.
The Lancet. Infectious Diseases|July 7, 2015
Risk factors for 30-day mortality in patients with pneumonia who receive appropriate initial antibiotics: an observational cohort studyYuichiro Shindo, Ryota Ito, Daisuke Kobayashi, et al.
American Journal of Respiratory and Critical Care Medicine|July 17, 2013
Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumoniaYuichiro Shindo, Ryota Ito, Daisuke Kobayashi, et al.
International Journal of Hematology|May 4, 2022
Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trialYasushi Miyazaki, Toru Kiguchi, Shinya Sato, et al.
Leukemia|January 7, 2026
NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partnersKazuhisa Chonabayashi, Makoto Iwasaki, Junya Kanda, et al.
Pageof 10